Dire need for a rational pricing system for new drugs
By Nho, Byung Chul | translator Alice Kang
21.12.07 06:29:00
가나다라
0
Global pricing standard = ‘Cost of production + α’… need to raise the companies' will for R&D
Japan and Taiwan provide 10% pricing premium for companies that conduct Phase III trials in their country…good ‘role model’
Can review reducing scope of alternative drugs, refund system, price discount accumulation system, etc.
Improving the drug pricing system through social consensus has been proposed as a prerequisite for the government to achieve the 60 trillion won export and 300,000 job creation in the biohealth industry as one of its 3 new growth engine industries.
In addition to the primary purpose of fostering the biopharmaceutical industry to create national wealth, there is no disagreement on the fact that the localization of vaccines and treatments as the nation’s key industry is essential to address the national need and respect and realize the right to life of the citizens in Korea in the COVID-19 pandemic.
In particular, the emphasis Yong-Ik Kim, the President of the National Health Ins
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)